UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population

被引:0
作者
Nancy Hakooz
Sameh Alzubiedi
Al-Motassem Yousef
Tawfiq Arafat
Rana Dajani
Nidaa Ababneh
Said Ismail
机构
[1] University of Jordan,Faculty of Pharmacy
[2] Zarqa University,Faculty of Pharmacy
[3] Jordan Center for Pharmaceutical Research,Biology Department
[4] Hashemite University,Faculty of Medicine
[5] University of Jordan,undefined
来源
Molecular Biology Reports | 2012年 / 39卷
关键词
Drug metabolism; Jordanian population; Polymorphism;
D O I
暂无
中图分类号
学科分类号
摘要
Glucuronidation is one of the most important phase II metabolic pathways. It is catalyzed by a family of UDP-glucuronosyltransferase enzymes (UGTs). One of the subfamilies is UGT1A. Allele frequencies in UGT1A4 differ among ethnic groups. The aim of this study was to determine the allelic frequency of two most common defective alleles: UGT1A4*2 and UGT1A4*3 in a Jordanian population. A total of 216 healthy Jordanian Volunteers (165 males and 51 females) were included in this study. Genotyping for UGT1A4*1, UGT1A4*2 and UGT1A4*3 was done using a well established polymerase chain reaction–restriction fragment length polymorphism test. Among 216 random individuals studied for UGT1A4*2 mutation there were 26 individuals who were heterozygous, giving a prevalence of 12% and an allele frequency of 6.5%. Only one individual was homozygous for UGT1A4*2. The UGT1A4*3 mutation was detected as heterozygous in 9 of 216 individuals indicating a prevalence of 4.2% and allele frequency of 3.5%. Three individuals were homozygous for the UGT1A4*3 indicating a prevalence of 1.4%. The prevalence of UGT1A4*2 is similar to the Caucasians but different from other populations whilst the UGT1A4*3 prevalence in the Jordanian population is distinct from other populations. Our results provide useful information for the Jordanian population and for future genotyping of Arab populations in general.
引用
收藏
页码:7763 / 7768
页数:5
相关论文
共 201 条
  • [1] Zhou SF(2009)Polymorphism of human cytochrome P450 enzymes and its clinical impact Drug Metab Rev 41 89-295
  • [2] Liu JP(2003)Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population Eur J Clin Pharmacol 59 303-312
  • [3] Chowbay B(2007)Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype–phenotype relationship in Swedes and Koreans Eur J Clin Pharmacol 63 537-546
  • [4] Gaikovitch EA(2011)Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population Genet Test Mol Biomarkers 15 827-830
  • [5] Cascorbi I(2011)Prevalence of CYP2C19 polymorphisms in the Lebanese population Mol Biol Rep 38 5449-5452
  • [6] Mrozikiewicz PM(2006)CYP3A phenotypes and genotypes in North Indians Eur J Clin Pharmacol 62 417-422
  • [7] Brockmoller J(2011)Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects Eur J Clin Pharmacol 67 39-45
  • [8] Frotschl R(2010)Genetic analysis of thiopurine methyltransferase polymorphism in the Jordanian population Eur J Clin Pharmacol 66 999-1003
  • [9] Kopke K(2011)Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on patients Int J Mol Med 28 1093-1102
  • [10] Gerloff T(2010)Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients Transplant Proc 42 3459-3464